{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:33:54Z","timestamp":1777649634384,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11824-9","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:45:33Z","timestamp":1777445133000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular dynamics simulations along with the synthesis of innovative engineered nanobodies targeting Interleukin-2"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3328-4746","authenticated-orcid":false,"given":"Mohammad Mehdi","family":"Heidari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4400-5305","authenticated-orcid":false,"given":"Aida","family":"Bemaninejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3742-5205","authenticated-orcid":false,"given":"Elahe Anbar","family":"Shirazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5840-5399","authenticated-orcid":false,"given":"Mehri","family":"Khatami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0036-0324","authenticated-orcid":false,"given":"Mahsa","family":"Mirzaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4196-0627","authenticated-orcid":false,"given":"Mersad","family":"Hajian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9100-9769","authenticated-orcid":false,"given":"Elnaz","family":"Showti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"2","key":"11824_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/iji.12654","volume":"51","author":"JJ Fernando","year":"2024","unstructured":"Fernando JJ, Biswas R, Biswas L (2024) Non-invasive molecular biomarkers for monitoring solid organ transplantation: A comprehensive overview. Int J Immunogenet 51(2):47\u201362. https:\/\/doi.org\/10.1111\/iji.12654","journal-title":"Int J Immunogenet"},{"key":"11824_CR2","doi-asserted-by":"publisher","unstructured":"Song X, Liang H, Nan F, Chen W, Li J, He L et al (2025) Autoimmune diseases: molecular pathogenesis and therapeutic targets. 6(7):e70262. https:\/\/doi.org\/10.1002\/mco2.70262","DOI":"10.1002\/mco2.70262"},{"issue":"6","key":"11824_CR3","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.3390\/curroncol30060430","volume":"30","author":"A Kulbat","year":"2023","unstructured":"Kulbat A, Richter K, Stefura T, Ko\u0142odziej-Rzepa M, Kisielewski M, Wojewoda T et al (2023) Systematic review of calcineurin inhibitors and incidence of skin malignancies after kidney transplantation in adult patients: a study of 309,551 cases. Curr Oncol 30(6):5727\u20135737","journal-title":"Curr Oncol"},{"key":"11824_CR4","doi-asserted-by":"publisher","first-page":"115429","DOI":"10.1016\/j.intimp.2025.115429","volume":"165","author":"MBS Gon\u00e7alves","year":"2025","unstructured":"Gon\u00e7alves MBS, Fonseca M, Mascarenhas-Melo F, Figueiras A (2025) Advancing insights into psoriasis: from pathogenesis to current and emerging therapies. Int Immunopharmacol 165:115429. https:\/\/doi.org\/10.1016\/j.intimp.2025.115429","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"11824_CR5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/nri3156","volume":"12","author":"O Boyman","year":"2012","unstructured":"Boyman O, Sprent J (2012) The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 12(3):180\u2013190","journal-title":"Nat Rev Immunol"},{"key":"11824_CR6","doi-asserted-by":"publisher","unstructured":"Rotte A, Bhandaru M, Zhou Y, McElwee KJ (2015) Immunotherapy of melanoma: present options and future promises. Cancer Metastasis 34(1):115\u201328 https:\/\/doi.org\/10.1007\/s10555-014-9542-0","DOI":"10.1007\/s10555-014-9542-0"},{"key":"11824_CR7","unstructured":"Wagner JA (2021) Mechanisms of Natural Killer Cell Anti-Tumor Function and Homeostasis. Washington University in St. Louis"},{"key":"11824_CR8","doi-asserted-by":"publisher","first-page":"1433989","DOI":"10.3389\/fimmu.2024.1433989","volume":"15","author":"S Rokade","year":"2024","unstructured":"Rokade S, Damani AM, Oft M, Emmerich J (2024) IL-2 based cancer immunotherapies: An evolving paradigm. Front Immunol 15:1433989","journal-title":"Front Immunol"},{"issue":"5","key":"11824_CR9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41435-023-00221-y","volume":"24","author":"V Lykhopiy","year":"2023","unstructured":"Lykhopiy V, Malviya V, Humblet-Baron S, Schlenner SM (2023) IL-2 immunotherapy for targeting regulatory T cells in autoimmunity. Genes Immun 24(5):248\u2013262. https:\/\/doi.org\/10.1038\/s41435-023-00221-y","journal-title":"Genes Immun"},{"key":"11824_CR10","doi-asserted-by":"publisher","unstructured":"Han X, Jiang Y, Gu S, Shen Y, Ding H, Chen S et al (2025) IL-2 signalling sustains pathogenic age-associated B cell homeostasis in lupus. Annals of the Rheumatic Diseases. https:\/\/doi.org\/10.1016\/j.ard.2025.08.012","DOI":"10.1016\/j.ard.2025.08.012"},{"issue":"4","key":"11824_CR11","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/JLB.2RI0717-278R","volume":"103","author":"S Mitra","year":"2018","unstructured":"Mitra S, Leonard WJ (2018) Biology of IL-2 and its therapeutic modulation: Mechanisms and strategies. J Leukoc Biol 103(4):643\u2013655","journal-title":"J Leukoc Biol"},{"key":"11824_CR12","first-page":"19","volume":"18","author":"E Hasanov","year":"2020","unstructured":"Hasanov E, Diab A, Tannir N (2020) Back to interleukin 2 after four decades: review of the history, biology, novel approaches and clinical trials. Kidney Cancer J 18:19\u201324","journal-title":"Kidney Cancer J"},{"issue":"2","key":"11824_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","volume":"78","author":"M Rosenzwajg","year":"2019","unstructured":"Rosenzwajg M, Lorenzon R, Cacoub P, Pham HP, Pitoiset F, El Soufi K et al (2019) Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis 78(2):209\u2013217","journal-title":"Ann Rheum Dis"},{"issue":"11 Suppl 13","key":"11824_CR14","first-page":"11","volume":"16","author":"RN Schwartz","year":"2002","unstructured":"Schwartz RN, Stover L, Dutcher JP (2002) Managing toxicities of high-dose interleukin-2. Oncol (Williston Park NY) 16(11 Suppl 13):11\u201320","journal-title":"Oncol (Williston Park NY)"},{"issue":"12","key":"11824_CR15","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1517\/14712598.6.12.1323","volume":"6","author":"O Boyman","year":"2006","unstructured":"Boyman O, Surh CD, Sprent J (2006) Potential use of IL-2\/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opin Biol Ther 6(12):1323\u20131331","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"11824_CR16","doi-asserted-by":"publisher","first-page":"1899671","DOI":"10.1080\/2162402X.2021.1899671","volume":"10","author":"J Kim","year":"2021","unstructured":"Kim J, Lee J-Y, Park S-Y, Lee YJ, Kim M-S (2021) Crystal structure of human interleukin-2 in complex with TCB2, a new antibody-drug candidate with antitumor activity. Oncoimmunology 10(1):1899671","journal-title":"Oncoimmunology"},{"issue":"5769","key":"11824_CR17","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1126\/science.1122927","volume":"311","author":"O Boyman","year":"2006","unstructured":"Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J (2006) Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311(5769):1924\u20131927. https:\/\/doi.org\/10.1126\/science.1122927","journal-title":"Science"},{"issue":"5","key":"11824_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.tibtech.2014.03.001","volume":"32","author":"T De Meyer","year":"2014","unstructured":"De Meyer T, Muyldermans S, Depicker A (2014) Nanobody-based products as research and diagnostic tools. Trends Biotechnol 32(5):263\u2013270","journal-title":"Trends Biotechnol"},{"issue":"1","key":"11824_CR19","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/imr.13385","volume":"328","author":"F Koch-Nolte","year":"2024","unstructured":"Koch-Nolte F (2024) Nanobody\u2010based heavy chain antibodies and chimeric antibodies. Immunol Rev 328(1):466\u2013472","journal-title":"Immunol Rev"},{"issue":"7","key":"11824_CR20","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1111\/febs.15515","volume":"288","author":"S Muyldermans","year":"2021","unstructured":"Muyldermans S (2021) A guide to: generation and design of nanobodies. FEBS J 288(7):2084\u20132102","journal-title":"FEBS J"},{"key":"11824_CR21","doi-asserted-by":"publisher","first-page":"1399438","DOI":"10.3389\/fimmu.2024.1399438","volume":"15","author":"GL Gordon","year":"2024","unstructured":"Gordon GL, Raybould MIJ, Wong A, Deane CM (2024) Prospects for the computational humanization of antibodies and nanobodies. Front Immunol 15:1399438. https:\/\/doi.org\/10.3389\/fimmu.2024.1399438","journal-title":"Front Immunol"},{"issue":"1","key":"11824_CR22","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1186\/s12951-024-02900-y","volume":"22","author":"E Alexander","year":"2024","unstructured":"Alexander E, Leong KW (2024) Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years. J Nanobiotechnol 22(1):661. https:\/\/doi.org\/10.1186\/s12951-024-02900-y","journal-title":"J Nanobiotechnol"},{"issue":"11","key":"11824_CR23","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.3390\/ijms19113444","volume":"19","author":"HJ Wagner","year":"2018","unstructured":"Wagner HJ, Wehrle S, Weiss E, Cavallari M, Weber W (2018) A two-step approach for the design and generation of nanobodies. Int J Mol Sci 19(11):3444","journal-title":"Int J Mol Sci"},{"key":"11824_CR24","doi-asserted-by":"publisher","first-page":"109736","DOI":"10.1016\/j.bej.2025.109736","volume":"219","author":"MM Heidari","year":"2025","unstructured":"Heidari MM, Khatami M, Soltanzade A, Rezaei S, Mirhashemi E (2025) New strategy for the design and cloning of novel humanized biparatopic anti-CD52 nanobodies: Tools for targeted drug delivery and therapeutic approaches. Biochem Eng J 219:109736","journal-title":"Biochem Eng J"},{"issue":"1","key":"11824_CR25","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s11033-024-09684-2","volume":"51","author":"MM Heidari","year":"2024","unstructured":"Heidari MM, Shirazi EA, Cheraghi SF, Shahshahani R, Rahnama T, Khatami M (2024) CDR grafting and site-directed mutagenesis approach for the generation and affinity maturation of Anti-CD20 nanobody. Mol Biol Rep 51(1):751","journal-title":"Mol Biol Rep"},{"key":"11824_CR26","doi-asserted-by":"publisher","unstructured":"Mirzaei M, Mirhoseini S (2025) Design and production of a novel anti-PD-1 nanobody by CDR grafting and site-directed mutagenesis approach. 67(5):1843\u20131851. https:\/\/doi.org\/10.1007\/s12033-024-01162-1","DOI":"10.1007\/s12033-024-01162-1"},{"issue":"1","key":"11824_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13568-023-01648-2","volume":"14","author":"A Beig Parikhani","year":"2024","unstructured":"Beig Parikhani A, Dehghan R, Talebkhan Y, Bayat E, Biglari A, Shokrgozar MA et al (2024) A novel nanobody-based immunocytokine of a mutant interleukin-2 as a potential cancer therapeutic. AMB Express 14(1):19","journal-title":"AMB Express"},{"issue":"2","key":"11824_CR28","first-page":"1","volume":"53","author":"X Zhang","year":"2024","unstructured":"Zhang X, Wang J, Tan Y, Chen C, Tang S, Zhao S et al (2024) Nanobodies in cytokine\u2013mediated immunotherapy and immunoimaging. Int J Mol Med 53(2):1\u201314","journal-title":"Int J Mol Med"},{"key":"11824_CR29","doi-asserted-by":"publisher","unstructured":"Kim J, Lee JY, Park SY, Lee YJ (2021) Crystal structure of human interleukin-2 in complex with TCB2, a new antibody-drug candidate with antitumor activity. 10(1):1899671. https:\/\/doi.org\/10.1080\/2162402x.2021.1899671","DOI":"10.1080\/2162402x.2021.1899671"},{"issue":"2","key":"11824_CR30","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.gene.2013.03.126","volume":"524","author":"P Zhang","year":"2013","unstructured":"Zhang P, Ding Y, Liao W, Chen Q, Zhang H, Qi P et al (2013) A simple, universal, efficient PCR-based gene synthesis method: sequential OE-PCR gene synthesis. Gene 524(2):347\u2013354","journal-title":"Gene"},{"issue":"1","key":"11824_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12943-023-01826-7","volume":"22","author":"S Muhammad","year":"2023","unstructured":"Muhammad S, Fan T, Hai Y, Gao Y, He J (2023) Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies. Mol Cancer 22(1):121. https:\/\/doi.org\/10.1186\/s12943-023-01826-7","journal-title":"Mol Cancer"},{"key":"11824_CR32","doi-asserted-by":"publisher","unstructured":"Trotta E, Bessette PH, Silveria SL, Ely LK, Jude KM (2018) A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism. 24(7):1005\u20131014. https:\/\/doi.org\/10.1038\/s41591-018-0070-2","DOI":"10.1038\/s41591-018-0070-2"},{"key":"11824_CR33","doi-asserted-by":"publisher","first-page":"874778","DOI":"10.3389\/fimmu.2022.874778","volume":"13","author":"E Lee","year":"2022","unstructured":"Lee E, Kim M, Lee YJ (2022) Selective expansion of tregs using the IL-2 cytokine antibody complex does not reverse established alopecia areata in C3H\/HeJ mice. Front Immunol 13:874778","journal-title":"Front Immunol"},{"issue":"7","key":"11824_CR34","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.molmed.2022.04.010","volume":"28","author":"Y Yuan","year":"2022","unstructured":"Yuan Y, Kolios AGA, Liu Y, Zhang B, Li H, Tsokos GC et al (2022) Therapeutic potential of interleukin-2 in autoimmune diseases. Trends Mol Med 28(7):596\u2013612. https:\/\/doi.org\/10.1016\/j.molmed.2022.04.010","journal-title":"Trends Mol Med"},{"key":"11824_CR35","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s00216-019-01633-4","volume":"411","author":"J-P Salvador","year":"2019","unstructured":"Salvador J-P, Vilaplana L, Marco M-P (2019) Nanobody: outstanding features for diagnostic and therapeutic applications. Anal Bioanal Chem 411:1703\u20131713","journal-title":"Anal Bioanal Chem"},{"key":"11824_CR36","doi-asserted-by":"publisher","first-page":"1488331","DOI":"10.3389\/fbinf.2024.1488331","volume":"4","author":"JR Devasani","year":"2025","unstructured":"Devasani JR, Guntuku G, Panatula N, Muthyala MKK, Palla MS, Siahaan TJ (2025) Innovative CDR grafting and computational methods for PD-1 specific nanobody design. Front Bioinf 4:1488331","journal-title":"Front Bioinf"},{"key":"11824_CR37","unstructured":"Ayrton J-P (2025) Engineering nanobody fusion proteins for nanoparticle stabilisation and application in biosensing, UCL (University College London)"},{"key":"11824_CR38","doi-asserted-by":"publisher","unstructured":"Lodge J, Kajtar L, Duxbury R, Hall D, Burley GA, Cordy J et al (2025) Quantifying antibody binding: techniques and therapeutic implications. 17(1):2459795. https:\/\/doi.org\/10.1080\/19420862.2025.2459795","DOI":"10.1080\/19420862.2025.2459795"},{"key":"11824_CR39","doi-asserted-by":"publisher","unstructured":"Karakus U, Sahin D (2020) Receptor-gated IL-2 delivery by an anti-human IL-2 antibody activates regulatory T cells in three different species. 12. https:\/\/doi.org\/10.1126\/scitranslmed.abb9283","DOI":"10.1126\/scitranslmed.abb9283"},{"key":"11824_CR40","unstructured":"Sur\u00f3wka MK (2025) Development and characterization of universal and modular bispecific immune cell engagers for cancer immunotherapy, lmu"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11824-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11824-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11824-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:45:38Z","timestamp":1777445138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11824-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11824"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11824-9","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No humans or animals were used in the present research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"691"}}